<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5CA4F84F-234A-4634-9295-37F610DCCAA7"><gtr:id>5CA4F84F-234A-4634-9295-37F610DCCAA7</gtr:id><gtr:firstName>Joanne</gtr:firstName><gtr:surname>Tod</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002008"><gtr:id>1FC82AE1-6067-45F2-B2F1-321F4D028790</gtr:id><gtr:title>The role of Eps8 in regulating pancreatic cancer invasion</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002008</gtr:grantReference><gtr:abstractText>The spread of malignant cells locally (tumour invasion) is fundamental to cancer development and progression. Pancreatic adenocarcinoma (PAC) has one of the worst outcomes of any cancer; only 3% of patients survive for 3 years, and 50% of patients die within 6 months. Less than 20% of patients are suitable for surgical treatment, and this is because, by the time that PAC is diagnosed, it has spread into adjacent tissues, making surgery impossible. 
We, and others, have shown that the proteins Eps8 and integrin v 6 are upregulated in a number of different cancer types, including PAC. More recently, we have shown a link between Eps8 and v 6 in regulating the movement of pancreatic cancer cells, although we have not yet identified the mechanism(s) controlling the invasive process. The aim of this study is to determine how the two proteins interact to promote PAC cell movement. 

Understanding this process will give crucial insight into the biology of tumour cell invasion, and may uncover novel targets for the treatment and/or prevention of PAC</gtr:abstractText><gtr:technicalSummary>Background: Pancreatic adenocarcinoma has one of the worst prognoses of any cancer, with a 5-yr survival rate of 3% and a median survival of &amp;lt;6 months. Less than 20% of patients present with localised disease treatable by surgery, and even then, 5-year survival remains low (20%)1. It is clear that new molecular-based treatments are required

Eps8 is a multifunctional protein, central to actin cytoskeletal reorganisation. Although the biochemistry of Eps8 has been investigated, its regulation and functional role in cells is less well understood, particularly in tumours. Recently we identified a functional link between tumour motility, Rac1 activation and Eps8. This was the first study showing that Eps8 can regulate collective tumour invasion in a physiologically relevant 3-D assay. 

Preliminary data: Our preliminary unpublished data show that Eps8 promotes PAC cell motility, and this is modulated through the integrin v 6, which is upregulated in numerous carcinomas, particularly PAC, where over 60% of tumours express the integrin strongly. We were the first to show that ?v?6 promotes tumour invasion, and further discovered that this process is modulated through activation of the small GTP-ase, Rac1, and requires integrin internalisation. Since Eps8 regulates GTP-ase activation, actin reorganisation and receptor endocytosis, ii may be of central importance in modulating v 6-dependent cell functions

Aims: The aim of this project is to determine the mechanism(s) by which Eps8 links integrin signalling, regulation of the actin cytoskeleton and cell function. 

Objectives and methodology: We will examine the expression and distribution of Eps8, and ?v?6 in human PAC, and relate these findings to disease development and progression. We will identify the Eps8 binding partners in PAC cells, before dissecting the mechanism(s) by which Eps8 modulates ?v?6-dependent invasion: specifically examining its role in GTP-ase activation, integrin endocytosis and integrin-dependent TGF- 1 activation. The effect of Eps8-dependent actin bundling and capping on PAC invasion will also be examined. Finally we will use PAC models to examine the functional role of the Eps8/ ?v?6 axis in vivo.

Scientific and medial opportunities: This study may uncover novel targets for the treatment and/or prevention of PAC, and will also give crucial insight into the general biology of tumour cell invasion.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>220627</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited Lecturer at All Party Parliamentary Group on Pancreatic Cancer meeting at the House of Commons</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1F6E9708-2757-4F7A-B4AB-5C67EAACACB9</gtr:id><gtr:impact>30 people attended the APPG on Pancreatic Cancer at the House of Commons where I gave a presentation outlining the challenges of pancreatic cancer research.

The APPG announced that it would be holding an Inquiry into Pancreatic Cancer Research</gtr:impact><gtr:outcomeId>5386fbd361c968.58975256</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.publications.parliament.uk/pa/cm/cmallparty/register/pancreatic-cancer.htm</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Pancreatic Cancer UK Supporters Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0DACC767-2E6A-45C0-9DC4-AC4987EA6EDD</gtr:id><gtr:impact>40 members of the public who support pancreatic cancer UK attended as supporters day where I presented 'The role of the tumour microenvironment in pancreatic cancer' - the presentation was well received and sparked a long question and answer session. As a result of the talk PCUK asked me to present in the House of Commons at the All Party Parliamentary Group on Pancreatic Cancer.

Feedback from audience:

Comments from Session 2 - Dr Jo Tod
&amp;quot; The Golden Nugget of the Day - Excellent&amp;quot;
&amp;quot; I thought Dr Jo Tod's presentation was really excellent, she put it across in a way we could all understand, such a clever and talented young lady. Very, very good&amp;quot;
&amp;quot; Fantastic presentation by Dr Tod. Very informative, would really appreciate the slides if possible.&amp;quot;
&amp;quot; Dr Jo Tod was incredibly easy to understand and changed how I view the disease&amp;quot;
&amp;quot;Brilliant - well done&amp;quot;
&amp;quot;Excellent session, so informative&amp;quot;
&amp;quot;Dr Tod was very informative, gave a greater understanding of pc&amp;quot;
&amp;quot;Quite technical information for a lay person but still very interesting&amp;quot;
&amp;quot;Very interesting to get a medical insight into the illness and a great explanation of the complications and reasons for it being so hard to treat. Also gives hope to see Dr Tod being so passionate about pancreatic cancer&amp;quot;
&amp;quot;What a fabulous presenter Jo is, articulate, informative, pitched just right so that I could understand&amp;quot;</gtr:impact><gtr:outcomeId>53862d27c40c67.45342645</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.pancreaticcancer.org.uk/media/534194/1969_pcuk_newsletter_spring2014__2_.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>International Travel Bursary</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Pancreatic Society of Great Britain and Ireland (PanSoc)</gtr:fundingOrg><gtr:id>F0632335-FB10-49D3-AF44-87D948487C64</gtr:id><gtr:outcomeId>5385f2c9c904e7.54050255</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Southampton Travel Award</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>University of Southampton</gtr:fundingOrg><gtr:id>D363906C-0434-470B-842A-53CD93E79E4D</gtr:id><gtr:outcomeId>5385f3aa81d2d6.15802279</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Young Investigator Travel Award</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>American Pancreatic Association (APA)</gtr:fundingOrg><gtr:id>E363F2DA-9874-467C-A51C-BA8B1996749B</gtr:id><gtr:outcomeId>5385f357219c79.49798813</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Future Leaders Award</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Pancreatic Cancer UK</gtr:fundingOrg><gtr:id>BF3EEB61-FF86-40DF-9FFE-CF9369926DE7</gtr:id><gtr:outcomeId>5386fe17ac4894.85615283</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1A71AE23-3E24-47EB-BFA7-E76159AB85AE</gtr:id><gtr:title>Tumor-stromal interactions in pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/678def8e4bad9138832da1839f7e064a"><gtr:id>678def8e4bad9138832da1839f7e064a</gtr:id><gtr:otherNames>Tod J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1424-3903</gtr:issn><gtr:outcomeId>pm_14146_26_23395563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B89FD2F-9F79-4339-8B0F-00996B5A3A7F</gtr:id><gtr:title>Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ef9332f0a661b0b591c18c9609a6908"><gtr:id>3ef9332f0a661b0b591c18c9609a6908</gtr:id><gtr:otherNames>Moutasim KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_14146_26_24573955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A740273B-7009-4DA9-BF39-9F313C8F6AA7</gtr:id><gtr:title>Pro-migratory and TGF-?-activating functions of av?6 integrin in pancreatic cancer are differentially regulated via an Eps8-dependent GTPase switch.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/678def8e4bad9138832da1839f7e064a"><gtr:id>678def8e4bad9138832da1839f7e064a</gtr:id><gtr:otherNames>Tod J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5a2fd39099e377.21850691</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002008</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>